Aureus Asset Management Has Trimmed Boston Scientific Com (BSX) Stake; Franklin Resources Increased Array Biopharma (ARRY) Stake By $23.35 Million

December 7, 2017 - By Louis Casey

Aureus Asset Management Llc decreased Boston Scientific Corp Com (BSX) stake by 18.96% reported in 2017Q2 SEC filing. Aureus Asset Management Llc sold 135,640 shares as Boston Scientific Corp Com (BSX)’s stock rose 4.02%. The Aureus Asset Management Llc holds 579,918 shares with $16.08M value, down from 715,558 last quarter. Boston Scientific Corp Com now has $34.67B valuation. The stock increased 0.04% or $0.01 during the last trading session, reaching $25.25. About 1.21 million shares traded. Boston Scientific Corporation (NYSE:BSX) has risen 19.12% since December 7, 2016 and is uptrending. It has outperformed by 2.42% the S&P500.

Franklin Resources Inc increased Array Biopharma Inc (ARRY) stake by 48.37% reported in 2017Q2 SEC filing. Franklin Resources Inc acquired 2.92M shares as Array Biopharma Inc (ARRY)’s stock declined 27.53%. The Franklin Resources Inc holds 8.95 million shares with $74.92M value, up from 6.03 million last quarter. Array Biopharma Inc now has $2.12B valuation. The stock increased 1.61% or $0.17 during the last trading session, reaching $10.75. About 148,360 shares traded. Array BioPharma Inc. (NASDAQ:ARRY) has risen 176.51% since December 7, 2016 and is uptrending. It has outperformed by 159.81% the S&P500.




Investors sentiment decreased to 1.16 in Q2 2017. Its down 0.16, from 1.32 in 2017Q1. It dived, as 27 investors sold ARRY shares while 48 reduced holdings. 32 funds opened positions while 55 raised stakes. 165.02 million shares or 0.80% more from 163.71 million shares in 2017Q1 were reported. Tudor Investment Corp Et Al owns 73,373 shares. Putnam Limited Company has invested 0.02% in Array BioPharma Inc. (NASDAQ:ARRY). National Bank Of Montreal Can holds 164,408 shares or 0% of its portfolio. Hollencrest Secs Lc owns 0.18% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 141,470 shares. Raymond James Svcs Advisors invested 0% in Array BioPharma Inc. (NASDAQ:ARRY). Airain accumulated 38,866 shares. Janney Montgomery Scott Limited Liability Corporation owns 0% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 24,250 shares. United Services Automobile Association reported 569,000 shares. Credit Suisse Ag has invested 0% in Array BioPharma Inc. (NASDAQ:ARRY). Macquarie Group stated it has 330,000 shares or 0.01% of all its holdings. Pura Vida Investments Limited Co has 265,589 shares. Fin Architects reported 1,400 shares or 0% of all its holdings. Sabby Mgmt Limited Liability owns 0.09% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 155,757 shares. Loring Wolcott And Coolidge Fiduciary Advsrs Limited Liability Partnership Ma owns 6,000 shares for 0% of their portfolio. Baxter Bros Incorporated owns 14,200 shares.

Among 10 analysts covering Array BioPharma (NASDAQ:ARRY), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Array BioPharma had 29 analyst reports since June 3, 2016 according to SRatingsIntel. Piper Jaffray maintained the shares of ARRY in report on Wednesday, May 31 with “Buy” rating. The rating was maintained by Piper Jaffray with “Overweight” on Monday, September 26. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Piper Jaffray on Wednesday, November 29. The firm earned “Buy” rating on Tuesday, October 31 by SunTrust. The stock has “Buy” rating by Jefferies on Thursday, August 24. The firm earned “Buy” rating on Tuesday, October 31 by Stifel Nicolaus. The company was maintained on Friday, August 5 by Stifel Nicolaus. The rating was maintained by Jefferies on Thursday, July 13 with “Buy”. Cowen & Co maintained Array BioPharma Inc. (NASDAQ:ARRY) rating on Tuesday, October 31. Cowen & Co has “Buy” rating and $15.0 target. The stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Stifel Nicolaus on Friday, February 3.

Franklin Resources Inc decreased Retail Pptys Amer Inc (NYSE:RPAI) stake by 106,300 shares to 672,500 valued at $8.21M in 2017Q2. It also reduced Bank Montreal Que (NYSE:BMO) stake by 35,361 shares and now owns 5.25M shares. Cloud Peak Energy Inc (NYSE:CLD) was reduced too.

Among 28 analysts covering Boston Scientific Corporation (NYSE:BSX), 23 have Buy rating, 0 Sell and 5 Hold. Therefore 82% are positive. Boston Scientific Corporation had 78 analyst reports since July 27, 2015 according to SRatingsIntel. On Monday, August 10 the stock rating was reinitiated by Credit Suisse with “Outperform”. The firm earned “Hold” rating on Monday, June 26 by BTIG Research. The firm earned “Buy” rating on Monday, September 25 by Stifel Nicolaus. The company was maintained on Wednesday, November 29 by Stifel Nicolaus. The stock of Boston Scientific Corporation (NYSE:BSX) earned “Hold” rating by Jefferies on Wednesday, November 29. Wedbush maintained Boston Scientific Corporation (NYSE:BSX) on Thursday, April 28 with “Neutral” rating. Oppenheimer maintained the shares of BSX in report on Monday, May 1 with “Hold” rating. Oppenheimer maintained the shares of BSX in report on Wednesday, June 28 with “Hold” rating. The rating was maintained by Wedbush on Friday, July 29 with “Neutral”. The rating was maintained by Needham on Wednesday, October 28 with “Buy”.

Analysts await Boston Scientific Corporation (NYSE:BSX) to report earnings on February, 1. They expect $0.34 earnings per share, up 13.33% or $0.04 from last year’s $0.3 per share. BSX’s profit will be $466.88 million for 18.57 P/E if the $0.34 EPS becomes a reality. After $0.31 actual earnings per share reported by Boston Scientific Corporation for the previous quarter, Wall Street now forecasts 9.68% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: